ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings

Contributed by: Business Wire

Logo

Business Wire logo

Images

Dr. Rudolf Widmann, Founder of AOP Health, Photo credit: AOP Health/Studio Koekart
Dr. Rudolf Widmann, Founder of AOP Health, Photo credit: AOP Health/Studio Koekart
Business Wire embedded0

Tags

Science
Biotechnology
Research
Pharmaceutical
Oncology
General Health
Health
Clinical Trials
AOP Health

More Like This

Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health

Portrait: Dr. Rudolf Widmann | Member of the Board of Directors & Founder | AOP Health | Photocredit: AOP Health | Ospelt Photography

ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

Professor Heinz Gisslinger, MedUni Vienna/Austria (Fotocredit: IntMedCom)

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting

AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart)

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

Rare Diseases: Collaboration is key. image: AdobeStock_1308212316

AOP Health on Rare Diseases: Information. Collaboration. Innovation.

Group photo management AOP Health and RHEACELL, from left to right: Dr. Christoph Ganss, Dr. Andreas Kluth, RHEACELL Dr. Rudolph Widmann, Dr. Günther Krumpl, Dr. Martin Steinhart, Bernhard Nachbaur, LL.M., AOP Health

RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds